This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

EU OKs J&J's $21.3B Synthes Takeover: Hot Trends

NEW YORK ( TheStreet) -- Popular searches on the Internet Thursday include Synthes after the European Union approved Johnson & Johnson's (JNJ - Get Report) $21.3 billion acquisition of the Swiss orthopedics maker.

The EU said J&J's planned sale of its trauma business would ensure the combined companies would continue to face competition and leave enough alternatives for doctors and patients.

Synthes is J&J's largest acquisition to date. U.S. regulators have not yet approved the deal.

J&J offered to buy Synthes in April 2011 for 159 Swiss francs a share in cash and stock. It plans to sell its global trauma business to Biomet for $280 million in cash.

Ford (F - Get Report) is trending as the automaker is planning a new $760 million assembly plant in China that is expected to double its output in the country.

Construction on the plant will start later this year and should open in 2015. Though it will initially produce 250,000 vehicles a year, Ford expects the plant to eventually double its production to 1.2 million vehicles annually.

The factory makes Ford's total investment in China now $4.9 billion. The company plans to bring 15 new models and 20 new engines and transmissions to the country by 2015.

Human Genome Sciences (HGSI) is another popular topic after rejecting an unsolicited $2.6 billion bid from GlaxoSmithKline (GSK - Get Report). Human Genome said the $13-a-share cash offer "does not reflect the value inherent" in the company.

Human Genome said its board has authorized exploring strategic alternatives, include a possible sale of the company, and GlaxoSmithKline has been invited to participate in the process.

The two companies are partners on lupus treatment Benlysta, which was approved by U.S. and European regulators last year. The companies are also collaborating on two other experimental drugs.

The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar.
Brittany joined TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
F $13.56 0.00%
GSK $42.91 0.00%
JNJ $112.08 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs